Previous 10 | Next 10 |
home / stock / rhhby / rhhby news
UCB S.A. ( OTCPK:UCBJF ) inks an agreement with Roche ( OTCQX:RHHBY ) and Genentech granting the parties exclusive global development and commercialization rights to UCB107 for the potential treatment of Alzheimer's disease (AD). More news on: UCB SA, Roche Holding AG, UCB SA, Health...
A Phase 3 clinical trial, COVACTA , evaluating Roche's ( OTCQX:RHHBY ) Actemra (tocilizumab) in adult patients with severe COVID-19 pneumonia failed to achieve the primary endpoin t of improved clinical status by day 28. Specifically, there was no statistically significant difference in ...
– COVACTA trial did not meet its primary endpoint of improved clinical status in patients with COVID-19 associated pneumonia or the key secondary endpoint of reduced patient mortality – – The study is the first global, randomized, controlled Phase III trial investi...
Step One: Wide-moat stocks with 5-star and 4-star ratings Historical evidence says that while quality alone is a poor indicator of outperformance, when combined with a decent valuation filter, Morningstar's moat rating proves to be more than useful. Based on the available data, stocks wi...
COM701 Exhibits Compelling Anti-Tumor Activity in Diverse, Challenging Patient Population After languishing for the better part of five years, Compugen ( CGEN ) shares are up 140% YTD and more than 300% over the past 52 weeks. This recent price action is directly attributable to the firs...
The first patients have been enrolled in a Phase 2 clinical trial, IONIC, evaluating Immunic's (NASDAQ: IMUX ) oral DHODH inhibitor IMU-838 (vidofludimus calcium), combined with Roche's ( OTCQX:RHHBY ) Tamiflu (oseltamivir phosphate) in COVID-19 patients. More news on: Immunic, ...
Foreword Any collection of stocks is more clearly understood when subjected to yield-based (dog catcher) analysis, these Barron's Mid-year Roundtable selections are perfect for the dogcatcher process. Here is the July 22 data for 24 dividend paying stocks out of 37 documented in the wh...
An outperformer over the past year, Swiss drug giant Roche ( OTCQX:RHHBY ) has given some of that back lately, with the shares underperforming the broader peer group over the last three months. Second quarter results aren’t going to help that, as the Covid-19 pandemic had a bigger tha...
Johnson & Johnson ( JNJ -0.1% ) unit Janssen Pharmaceutical Companies announces a positive opinion from the European Medicines Agency's advisory group CHMP backing the use of Imbruvica (ibrutinib), combined with rituximab [Roche's ( OTCQX:RHHBY ) Rituxan], for previously untreated ...
Start Time: 07:00 End Time: 08:45 Roche Holding AG (RHHBY) Q2 2020 Earnings Conference Call July 23, 2020, 07:00 AM ET Company Participants Severin Schwan - CEO Alan Hippe - Chief Financial and IT Officer Bill Anderson - CEO, Roche Pharmaceuticals Thomas Schinecker - CEO, R...
News, Short Squeeze, Breakout and More Instantly...
Roche Holding Ltd ADR Company Name:
RHHBY Stock Symbol:
OTCMKTS Market:
Wednesday, HOOKIPA Pharma Inc (NASDAQ:HOOK) received clearance from the FDA for its Investigational New Drug (IND) application for H...
– Results from the Phase III study showed that subcutaneous (SC) injection was consistent with IV infusion and demonstrated near-complete suppression of relapse activity (97%) and MRI lesions (97.2%) through 48 weeks – – The twice-yearly, 10-minute SC injection has th...
Monday, Roche Holdings AG (OTC:RHHBY) announced topline data from Phase 3 STARGLO study of Columvi (glofitamab) in combination ...